REEM KARMALI MD NPI 1083860282

NPI Details

Reem Karmali, MD is a hematology and oncology internal medicine in Chicago, IL with 20 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Reem Karmali, MD NPI is 1083860282. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

The provider's business location address is:

676 N SAINT CLAIR ST STE 850
CHICAGO, IL
ZIP 60611
Phone: (312) 695-0990

The NPI 1083860282 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, rituximab, 10 mg (HCPCS:J9312)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, bortezomib, not otherwise specified, 0.1 mg (HCPCS:J9044)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Unclassified drugs (HCPCS:J3490)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:Q0221)
• Initial hospital inpatient care per day, typically 30 minutes (HCPCS:99221)
• Injection of drug or substance into vein (HCPCS:96374)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)

The enumeration date for this NPI number is 8/7/2008 and was last updated on 11/13/2019.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: